Martolini, Galiè, Santoro, Monno, Santini, and Terracina: Antibiotic use in Departments of Internal Medicine of Lazio

Antibiotic use in Departments of Internal Medicine of Lazio

Abstract

Antimicrobial therapy is inappropriate in 9 to 64% of the patients hospitalized. We evaluated the antibiotic use in Internal Medicine wards of an Italian region (Lazio) by a prospective multicenter, observational study. One thousand and nine patients were evaluated. Patients under antimicrobial treatment (PUAT) were 588 (58.2%), patients without treatment (PWT) 421 (41.8%). Infections were classified as community acquired (47.8%), hospital acquired (10.3%) or healthcare-associated (11.4%); the remaining 30.5% of infections did not receive any epidemiological classification. Samples for microbiological examination were collected in 41.6% of PUAT. The antibiotic choice was empiric in 94.8% of the cases and protected penicillins were selected in 48% of the cases. The mean duration of treatment was 9.5±6 standard deviation (SD) days. Only 6% of the patients switched from intravenous to oral therapy. Age, length of hospital stay and mortality were higher for PUAT than for PWT (mean age: 75.9±15 SD vs 74.2±15 SD years, P<0.02; length of hospital stay: 13.7±10.4 SD vs 10±8.4 SD days, P<0.01; mortality: 15.9% vs 3.1%). Antibiotic stewardship needs to be implemented all over the hospitals of Lazio region.




Introduction

Antibiotics are frequently prescribed in medical wards, representing among others, a considerable burden. Antimicrobial therapy and prophylaxis in hospitals have been reported to be incorrect or not indicated in 9 to 64% of the patients1 and a similar problem is described also in other settings such as nursing homes where, due to the lack of structural and human resources, antimicrobial prophylaxis is often used in an attempt to prevent infections.2 There are several reasons for evaluating the treatment as inappropriate: lack of evidence of active bacterial disease, empiric treatment of non-critical patients, treatment of colonized asymptomatic patients, selection of second-line antibiotics not microbiologically driven. The main consequences of excessive or inappropriate antimicrobial use of antibiotics is the increase in infection or colonization due to resistant strains (methicillin resistant Staphylococcus aureus, multi-drug resistant Gramnegative bacteria, Clostridium difficile and Candida); these infections are burdened with high mortality, prolonged hospitalization and a substantial increase in health care costs. Moreover, antimicrobial drug toxicity and drug interactions should also be computed.

The main goal of antimicrobial stewardship is to obtain the best clinical outcome minimizing toxicity and limiting the selective pressure on bacterial populations that drives the emergence of resistant strains. The programs of antimicrobial stewardship improve the appropriate use of antimicrobial agents promoting the selection of the optimal antimicrobial regimen, including dosing, duration of therapy and route of administration. Antimicrobial stewardship also reduces the costs attributable to suboptimal antimicrobial use. Quantitative monitoring of antimicrobial use in hospitals or hospital units and qualitative evaluation of antimicrobial treatment and prophylaxis in individual patients are pivotal in addressing the interventions.3-5 Based on these premises we were interested in evaluating the modality of use of antibiotics in the wards of Internal Medicine of several hospitals of Lazio (an Italian region), focusing on number of treated patients, appropriateness of indications, preferred antibiotic classes, and followed stewardship programs (i.e., deescalation and/or rotation of antimicrobials).

Materials and Methods

Twelve units of Internal Medicine from 9 hospitals spread throughout the Italian region of Lazio participated in this prospective, multicenter, observational study performed on behalf of FADOI Lazio - Area of Infectious Diseases. The protocol was approved by the Local Ethic Committee. Every unit nominated a referent physician for data collection. The study period was 12 months (from November 2014 to October 2015). The list of participating hospitals, with the names of unit directors and referent physicians are reported in Table 1. Every patient, or their relatives when legally in charge, signed an informed consent form before any datum was collected. A data record form of every patient discharged during the first week of every month was filled. Every month all record forms were sent to the coordination center in order to create a single database. All collected patients were divided into two main groups: patients who underwent antimicrobial treatment (PUAT) and patients without treatment (PWT). These two populations were compared in terms of age, length of hospital stay, and mortality. For the PUAT group, the reasons to start an antimicrobial treatment and the ward or department where it was started were recorded. The diagnosis of infection was considered as possible, probable or definite according to diagnostic criteria guidelines and to the judgement of the doctor in charge. Every infection was classified for the organ or site affected, but also epidemiologically, discriminating among community-acquired (CAI), hospital-acquired (HAI) and healthcare-associated infections (HCAI). Inflammatory markers as procalcitonin (PCT) and/or C-reactive protein (CRP) and microbiological examinations performed were also recorded for all patients in the PUAT group. The antimicrobial therapy was evaluated if targeted on a specific isolate or empiric, and modifications in terms of upgrade or downgrade following microbiological isolation were reported. The used antimicrobials, the route of administration and the length of therapy were also considered. According to the clinical and epidemiological diagnosis, the appropriateness of the antibiotic chosen was evaluated from two different authors.

Statistical analysis

Data are expressed as mean±standard deviation (SD). Data were investigated if normally or not normally distributed. Non-parametric Mann-Whitney’s test was used to compare two groups of non-parametric data. Kruskal-Wallis’ test was employed to compare several groups of parametric data. GraphPad Prism 5.0 (GraphPad Software, Inc. USA) was used for statistical analysis.

Results

From November 2014 to October 2015, in the first week of every month, 1009 patients (M/F, 515/494; mean age/range 75.2 years±15.2 SD) were discharged from the twelve Internal Medicine Units participating in the study and were evaluated. Out of them, 95% were addressed to the wards of Internal Medicine from the Emergency Department, 3% from other wards, 1.2% directly from community. PUAT group included 588 patients (58.2%) and PWT group 421 patients (41.8%). In 222 cases (37.7%) the antibiotic therapy was initiated at the Emergency Department and in 339 cases (57.6%) during the permanence in the Internal Medicine ward. The antibiotic choice was empiric in 94.8% of patients and culture-driven in 4.9% of patients. The reported reasons to start the antibiotic therapy were: definite infection in 245 patients (41.6%), probable infection in 93 patients (15.8%), possible infection in 97 patients (16.4%), fever in 50 (8.5%) and prevention in 103 patients (17.5%). The infections were classified as CAI and HAI in 47.8% and 10.3% of patients respectively and HCAI in 11.4%. The remaining 30.5% did not receive any epidemiological classification by the doctors in charge. The site of infection was available for 485 patients (Table 2). Mean age, length of stay and mortality were higher for PUAT compared to PWT [mean age PUAT vs PWT: 75.9±15 SD vs 74.2±15 SD years, P<0.02; length of hospital stay PUAT vs PWT: 13.7±10.4 SD vs 10±8.4 SD days, P<0.01; mortality PUAT vs PWT: 16.1% (95 deaths) vs 3.1% (13 deaths)]. CRP, PCT, or both were measured respectively in 72%, 26%, and 21% of PUAT. In the PUAT group, microbiological cultures were performed in 245 patients (41.6%) and 121 (49.3%) resulted positive. On the basis of culture isolates, empiric antibiotic regimens resulted inadequate in 41 patients (33.8%); no modification was suggested in the remaining 80 patients (66.1%). The change in antibiotic treatment was an escalation in 25 patients, a de-escalation in 9 patients, while 7 patients did not receive any change even if suggested by the culture results. Overall, among patients of the PUAT group, the antibiotics more frequently selected for empiric treatment were ampicillin-sulbactam (133 patients =27.4%), ceftriaxone (102 patients =21%), fluoroquinolones (92 patients =18.9%) and piperacillin-tazobactam (81 patients =16.7%); carbapenems and glycopeptides were used in 4% and 3% of patients respectively. Most of the patients started the antimicrobial therapy intravenous (97%) to switch to oral therapy just few times (6%). The mean duration of antibiotic treatment in hospital was 9.5±6.1 SD days. Moreover, 18% of patients continued the treatment at home for further 6 days on average. In Table 3 are reported the different empiric therapeutic approaches for CAIs, HAIs, HCAIs and not epidemiologically classified infections (NECIs). CAIs were treated with ampicillin/sulbactam or amoxicillin/clavulanate (33%), fluoroquinolones (18.6%), piperacillin/tazobactam (18.1%), ceftriaxone (17.6%) and various other antimicrobials (12%). Out of these, 37 (17%) received a combination of two or more antibiotics. HAIs were treated with fluoroquinolones (20.9%), ampicillin/sulbactam (18.6%), ceftriaxone (16.2%), piperacillin/ tazobactam (13.9%), meropenem (13.9%), and vancomycin (11.6%); combination with another antibiotic (clarithromycin, fluoroquinolones, teicoplanin, gentamycin, metronidazole, colistin) was made in 10 patients (23%). The antibiotic more frequently selected to treat HCAIs (n=50) was piperacillin/tazobactam (42%), followed by fluoroquinolones, ampicillin/sulbactam, ceftriaxone and metronidazole (12% each) and meropenem (8%); combination regimens (using fluoroquinolones, glycopeptides, macrolide and aminoglycoside) were administered in 21 patients (42%). For the treatment of NECIs (n=177) were administered ceftriaxone (28.8%), ampicillin/sulbactam or amoxicillin/ clavulanate (27.1%), fluoroquinolones (20.9%), piperacillin/tazobactam (8.4%); combination regimens were used in 32 patients (18%). As shown in Table 4, remarkable differences were observed comparing the data of the various centers. The rate of PUAT ranged from 13% to 75%, the length of hospital stay from 7.8±7.7 SD days to 16.6±12 SD days (P<0.001), the mean duration of antibiotic treatment in hospital from 6.8±4.3 SD days to 11.4±7.8 SD among the various hospitals (P<0.05).

Discussion

In our observational study, more than half (58.5%) of patients admitted to the Internal Medicine wards received antibiotic therapy. The percentage significantly differed in different centers, ranging from 13% to 71%. These data are representative of the heterogeneity among Internal Medicine units and confirm several previous reports. Cusini et al. reported in Switzerland a mean prevalence of 44% among all hospital departments (including surgical and medical areas), with a rate of 46% for medical wards; hematology-oncology wards reached the higher value (57%).1 The European Surveillance of Antimicrobial Consumption (ESAC) showed a mean prevalence of 30%, even if ranging from 19% to 59% between 20 European hospitals. Several other studies conducted during the period 1999-2008 found the rate of patients receiving antibiotics ranging between 16 to 49%, but data were based on different departments, pediatric included, and not only on Internal Medicine wards.6-14Although the number of patients treated with antibiotic in our Internal Medicine wards seems exceedingly high, a more specific comparison in terms of departments, patients, diseases and comorbidities should be useful to evaluate any antimicrobial misuse. However, our results seem to show some important understatements in terms of antibiotic stewardship. Despite it is well recognized that patients with hospital acquired and health-care associated infections should be empirically treated with antibiotics active against specific multidrug resistant pathogens (i.e., Pseudomonas spp. and methicillin resistant S. aureus), one third of the patients in our series did not receive any epidemiological classification. As a consequence, patients with CAI could have been treated with unnecessary broad-spectrum drugs and, otherwise, patients with HAI could have been undertreated. Our data actually show that almost twenty percent of patients with CAI received a treatment with antibiotics appropriate for HAI (e.g., piperacillin-tazobactam) and probably unnecessary. Conversely, more than half of HAIs and HCAIs received treatments, which should be reserved to CAIs, frequently (80% of cases) using a single agent. This under treatment exposes these patients to higher risk of failure (complications and/or death). Overall, the selected antimicrobials were considered inadequate in 30% of cases according to the epidemiological classification received. Moreover, microbiological diagnosis was attempted in less than half of patients in the PUAT group and was obtained in 50% of cultured patients; therefore, only 25% of all PUAT received an etiologic diagnosis. This can explain why almost all treatments were empiric and so few targeted (5%). In a multicenter interventional study, 27.3% of antibiotic courses were determined to be unjustified; a post-prescription intervention based on an audit and feedback approach in addition to current stewardship programs, lead the clinicians to accept recommendations to change or stop the antibiotics in 66.7% of cases.15 Compared to this trial, the inappropriateness of antibiotic prescription observed in our Internal Medicine wards was not so different. Excessive or inappropriate antimicrobial use increases morbidity, mortality, and healthcare costs including prolonged hospitalization.7-11 Our results might be in accordance with these premises because PUAT showed a significantly higher mortality and prolonged length of stay. However, PUAT were also significantly older then PWT and the higher mortality, as well as the prolonged length of stay, could also be attributable to comorbidities and lower performance status, rather than to the antibiotic misuse. In the attempt to prevent the development of C. difficile infections, the antibiotic stewardship program guidelines by the Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA) highlight as a priority to reduce the use of high-risk antibiotics such as clindamycin, 2nd and 3rd generation cephalosporins and fluoroquinolones.16-18 In our study, protected penicillins were the antibiotic of choice in almost half of the cases, but 3rd generation cephalosporins and fluoroquinolones still accounted for 45% of cases overall. Interventions to reduce and minimize the consumption of these high-risk antibiotics should be a major challenge. It is not surprising that almost all patients admitted to Internal Medicine wards have antibiotics administered for intravenous route. However, the early switch to oral therapy has several advantages such as reduced risk of cannula-related infections, reduced risk of thrombophlebitis, lower costs, reduction of hidden costs (cost of diluents, needles, syringes, nursing time, etc.) and earlier discharge. For all these reasons intravenous to oral switch is strongly advocated in clinically stable patients. In our series the switch occurred in only 6% of patients. Based on these data, an intervention addressed to this topic probably should be included in the local stewardship programs. Antibiotic consumption is strongly related to duration of therapy. In the last few years, several studies documented similar efficacy of short-course regimens compared to standard regimens. Antibiotic stewardship interventions aimed at reducing the duration of antibiotic therapy lead to similar clinical outcomes compared to pre-intervention period. Specifically, 7 and 10 days of treatment for inpatients with community acquired pneumonia were equally effective in terms of clinical outcome, length of stay and 30-day readmission rates.19,20 Similarly, for patients with ventilator associated pneumonia, 8-10 days of treatment have been proposed in substitution of the usual two weeks course21-23 and the same proposal has been made for patients with cellulitis, pyelonephritis and intra-abdominal infection.24-28 Moreover, IDSA/SHEA guidelines suggest using inflammatory biomarker as PCT to shorten antimicrobial exposure, especially in intensive care units. Even if PCT was measured only in 26% of PUAT and therefore underutilized, the duration of antibiotic treatment in our center was not far from the numbers highlighted in the previous studies, with a mean length among various hospitals of 9.5±6.1 SD days ranging from 6.8±4.3 SD days to 11.4±7.8 SD (P<0.05). Unfortunately, we were not able to relate the duration of treatment with the clinical outcome. It seems remarkable that around 18% of patients continued the treatment at home for further 6 days on average probably extending too long the antibiotic course.

Limitations

Our study has several limitations. The center responsible to collect all data records and to create a single database did not have any control over the other hospitals doctors and even if it was clearly highlighted the importance of scheduling every patient discharged during the recruitment period we are not sure if any was missed and therefore if a collecting bias is present. Not all centers recruited the same number of patients and the use of inflammatory markers (e.g., PCT) was very heterogeneous. The records were not always completely filled in and several info lacked. We did not evaluate comorbidities (e.g., Charlson comorbidity index), and complications related to antibiotic use (e.g., C. difficile infections, allergic reaction, acute kidney injury, etc.). The diagnosis made was not always clear and this did not allow us to properly evaluate the expected duration of therapy. Since it was not possible to estimate for every patient the diagnosis along with illness severity and associated comorbidities, comparing mortality and length of stay of PUAT vs PWT was not feasible.

Conclusions

Among patients admitted to Internal Medicine wards, more than half received antibiotic therapy. Compared to previous studies, this rate is probably too high. Moreover, a great variability was observed among several wards. Almost all patients were treated empirically, but one third did not receive any epidemiological classification, with the possible consequence of being under- or over-treated. Greater attention to the epidemiological classification should be recommended to drive the antibiotic choice. Switching from intravenous to oral antibiotic is still far from being a reality in Lazio, only 6% of patients belong to this group. According to the current trends to short-course regimen for most infections, the mean duration of 9.5 days, seems too long. Furthermore, many patients were discharged with prescription of antibiotics at home for almost another week. Inflammatory markers as PCT are not yet commonly used to reduce antibiotic utilization. Critical issues and possible corrective measure highlighted by this study have been summarized in Table 5. Antibiotic stewardship programs represent a primary objective to implement in the Internal Medicine wards of Lazio.

References

1. 

A Cusini, SK Rampini, V Bansal. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS One 2010;5:e14011.

2. 

M Giannella, S Tedeschi, M Bartoletti, P. Viale Prevention of infections in nursing homes: antibiotic prophylaxis versus infection control and antimicrobial stewardship measures. Expert Rev Anti Infect Ther 2016;14:219-30.

3. 

DM Schulte, A Sethi, R Gangnon. Risk factors for Candida colonization and Co-colonization with multidrug resistant organisms at admission. Antimicrob Resist Infect Control 2015;4:46.

4. 

E Raineri, A Pan, P Mondello. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008;36:283-90.

5. 

CC Lai, ZY Shi, YH Chen, FD Wang. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: a multicenter comparison. J Microbiol Immunol Infect 2016; 49:74-82.

6. 

F Ansari, M Erntell, H Goossens, P. Davey The European Surveillance of Antimicrobials Consumption (ESAC) point-prevalence survey of antibacterial use in 20 European Hospitals in 2006. Clin Infect Dis 2009;49: 1496-504.

7. 

DL Paterson. “Collateral damage” from cephalosporin or quinolone antibiotic therapy, Clin Infect Dis 2004;38: S341-5.

8. 

WC Albrich, DL Monnet, S. Harbarth Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004;10:514-7.

9. 

H Goossens, M Ferech, Stichele R Vander. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87.

10. 

S Malhotra-Kumar, C Lammens, S Coenen. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double blind, placebocontrolled study. Lancet 2007;369:482-90.

11. 

TP Lodise, PS McKinnon. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52: 113-22.

12. 

NY Lee, HC Lee, NY Ko. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007;28:713-9.

13. 

M Venditti, M Falcone, S Corrao. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009;150:19-26.

14. 

Thoracic Society; Infectious Diseases Society of America American. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare- associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.

15. 

SE Cosgrove, SK Seo, MK Bolon. Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention. Infect Control Hosp Epidemiol 2012;33:374-80.

16. 

TF Barlam, SE Cosgrove, LM Abbo. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51-77.

17. 

JM Cyriac, E. James Switch over from intravenous to oral therapy: a concise overview. J Pharmacol Pharmacother 2014;5:83-7.

18. 

MA Fischer, DH Solomon, JM Teich, J. Avorn Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. Arch Intern Med 2003;163:2585-9.

19. 

G Dimopoulos, DK Matthaiou, DE Karageorgopoulos. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008;68:1841-54.

20. 

E Avdic, LA Cushinotto, AH Hughes. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012;54:1581-7.

21. 

R Pugh, C Grant, RP Cooke, G. Dempsey Short-course versus prolonged-course antibiotic therapy for hospitalacquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011;(1):CD007577.

22. 

G Dimopoulos, G Poulakou, IA Pneumatikos. Short-versus long-duration antibiotic regimens for ventilatorassociated pneumonia: a systematic review and meta-analysis. Chest 2013;144:1759-67.

23. 

J Chastre, M Wolff, JY Fagon. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98.

24. 

MJ Hepburn, DP Dooley, PJ Skidmore. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-74.

25. 

T Sandberg, G Skoog, AB Hermansson. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and doubleblind, placebo-controlled, non-inferiority trial. Lancet 2012;380:484-90.

26. 

DA Talan, WE Stamm, TM Hooton. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90.

27. 

BA Runyon, JG McHutchison, MR Antillon. Shortcourse versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991;100:1737-42.

28. 

RG Sawyer, JA Claridge, AB Nathens. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015;372:1996-2005.

Table 1.

Participating Centers and Units.

Hospital Unit-Ward Director(s) Investigator(s)
Vannini - Roma (coordinator center) Claudio Santini Maurizia Galiè Dario Martolini Eleonora Pistella
Sandro Pertini - Roma Aldo Fierro David Terracina Anna Maria Santoro
Sant’Eugenio - Roma Filomena Pietrantoni Gianluca Pavoni
Fatebenefratelli Isola Tiberina - Roma Dario Manfellotto Danilo Monno
San Giovanni - Roma Rosa Maida Gianfranco Panetta Francesco Montella Alessandro Bozza Paolo Carfagna Agapito Tarasi
L. Parodi Delfino - Colleferro Ruggero Pastorelli Rosalba Cipriani
San Camillo de Lellis - Rieti Basilio Battisti Giovanna Giacchetti
Santa Maria Goretti - Latina Giuseppe Campagna Cecilia Cianfrocca
Montefiascone Bruno Mongiardo Alessandra Fiorentini
Table 2.

Sites of infection.

Site of infection No. of patients %
Respiratory tract 214 44
Urinary tract 68 14
Biliary tract 24 4.9
Gastro-intestinal tract 47 9.6
Skin and soft tissue 39 8
Sepsis 29 5.9
Others 9 1.8
NA 55 11.3

[i] NA, not available.

Table 3.

Empiric therapeutic approach for community-acquired, hospital-acquired, health care-associated and not-epidemiologically- classified infections.

CAIs (n=215) HAIs (n=43) HCAIs (n=50) NECIs (n=177)
Ampicillin-sulbactam or amoxicillin-clavulanate 71 (33.0%) 8 (18.6%) 6 (12.0%) 48 (27.1%)
Piperacillin-tazobactam 39 (18.1%) 6 (13.9%) 21 (42.0%) 15 (8.4%)
Ceftriaxone 38 (17.6%) 7 (16.2%) 6 (12.0%) 51 (28.8%)
Fluoroquinolones 40 (18.6%) 9 (20.9%) 6 (12.0%) 37 (20.9%)
Carbapenems - 6 (13.9%) 4 (8.0%) -
Vancomycin - 5 (11.6%) - -
Others 27 (12.5%) 2 (4.6%) 7 (14.0%) 26 (14.6%)
Combination therapy 37 (17.2%) 10 (23.2%) 21 (42.0%) 32 (18.0%)

[i] CAIs, community-acquired infections; HAIs, hospital-acquired infections; HCAIs, health care-associated infections; NECIs, not-epidemiologically-classified infections.

Table 4.

Comparison of different Hospitals.

Hospital PUAT (% total) Duration of therapy (days±SD) Length of stay (days±SD)
All centers 58.5 9.5±6.1 13.7±10.4
San Giovanni - Roma 55 8.2±5.7 11.2±8.9
Sant’Eugenio - Roma 60 10.1±4.6 10.1±5.6
Vannini - Roma 58 9.7±6.1 13.7±10.4
Sandro Pertini - Roma 71 11.4±7.8 16.6±12
Fatebenefratelli Isola Tiberina - Roma 75 9.7±6 11.6±9.3
L. Parodi Delfino - Colleferro 60 8.2±4.9 10.8±6.9
San Camillo de Lellis - Rieti 13 6.8±4.3 7.8±7.7
Montefiascone 50 9.2±1.7 12.5±5.2
Santa Maria Goretti - Latina 50 7.4±2.7 8.5±8.2

[i] PUAT, patients under antimicrobial treatment; SD, standard deviation.

Table 5.

Critical issues and possible corrective measure.

Reasons Corrective measures
Excessive consumption/excessive duration Diagnosis questionable Make efforts to better define diagnosis and make an epidemiological classification; do not treat colonized asymptomatic patients
Poor guidelines adherence Increase guidelines adherence, prefer short-course AT if advocate
Wrong antibiotic use Seek for an etiologic diagnosis, antimicrobial prophylaxis only in selected patients
Low use of biomarkers Use PCT to guide AT
Antimicrobial stewardship programs not considered Infectious disease specialist consultation, control on prescription, de-escalation therapy, switch-therapy, route of administration (prefer per os over i.v.)
Missed etiologic diagnosis Sample not collected Collect cultural samples at least once at first episode of fever or suspicious of infection
Collection under AT Collect cultural samples before starting AT
Type of pathology/type of cultural sample Collect culture from primary site of infection, blood culture always useful
Clostridium difficile AT not needed See: Excessive consumption/excessive duration corrective measure
Excessive duration See: Excessive consumption/excessive duration corrective measure
Frail patients Isolate patients with C. difficile in single room Use gloves Wash hand between patients contact
Biomarkers Low availability Increase availability and educate professional workers
Poor awareness of their use Use PCT level to start or stop AT

[i] AT, antibiotic therapy; PCT, procalcitonin; os, oral somministration; i.v., intravenous.

Abstract views:
223

Views:
PDF
44
HTML
60

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Dario Martolini, Maurizia Galiè, Anna Maria Santoro, Danilo Monno, Claudio Santini, David Terracina, on behalf of FADOI Lazio - Area of Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185